Bristol Myers’ (BMY) is striving hard for the label expansion of its key drugs. The company’s growth portfolio comprises ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

Bristol Myers' Reblozyl missed its primary goal in a Phase 3 anemia trial but showed positive secondary outcomes in ...

Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for ...

Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes ...

Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...

Reblozyl (luspatercept) was first approved by the FDA for treatment of anemia related to beta thalassemia in late Q4 2019. The royalties are paid to Acceleron by Bristol-Myers Squibb ( BMY ).

Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia receiving red blood cell (RBC) ...

SUMMIT, N.J.& CAMBRIDGE, Mass.---- Celgene Corporation and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration has approved REBLOZYL ® for the treatment of anemia in adult ...